Spravato Dosing Intervals
Spravato (esketamine) nasal spray requires a 5-minute rest period between use of each device during a single treatment session, and treatment sessions are scheduled at specific intervals depending on the treatment phase.
Intervals Between Devices Within a Single Session
During each treatment session, there must be a 5-minute rest between use of each nasal spray device 1. For a 56 mg dose, you use 2 devices with a 5-minute break between them. For an 84 mg dose, you use 3 devices with 5-minute breaks between each device.
Intervals Between Treatment Sessions
The dosing frequency varies by treatment phase and indication:
For Treatment-Resistant Depression (TRD)
Induction Phase (Weeks 1-4):
Maintenance Phase (Weeks 5-8):
- Administer once weekly 1
Extended Maintenance (Week 9 and beyond):
- Administer every 2 weeks OR once weekly based on individual response 1
- The dosing frequency should be individualized to the least frequent schedule that maintains remission/response 1
For Major Depressive Disorder with Acute Suicidal Ideation or Behavior
- Administer 84 mg twice per week for 4 weeks 1, 3
- Treatment beyond 4 weeks has not been systematically evaluated for this indication 1
Managing Missed Sessions
If a patient misses treatment sessions and depression symptoms have NOT worsened: Continue the current dosing schedule 1
If a patient misses sessions during maintenance treatment and depression symptoms HAVE worsened: Consider returning to the previous more frequent dosing schedule (e.g., if doses were missed during weekly dosing, revert to twice-weekly dosing) 1
Clinical Context
The flexibility in maintenance dosing reflects evidence showing that treatment frequency adjustments based on symptom response optimize outcomes. In the SUSTAIN-2 analysis, when patients transitioned from weekly to every-other-week dosing, 19% further improved, 49% maintained benefit, and 32% worsened. Importantly, when frequency was increased back to weekly for those who worsened, 47% improved again 4. This supports the protocol's built-in flexibility to adjust dosing intervals based on clinical response rather than rigid scheduling.
Critical safety requirement: Each treatment session requires at least 2 hours of post-administration observation under direct healthcare provider supervision before the patient can be discharged 1.